Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

A report from the solicitors representing the defendant health authority in the litigation recorded they were "unable" to show that cryoprecipitate and NHS Factor 8 concentrate were not available. Dr Martin "says that he gave no consideration to alternative treatment."

Published on: 30 September, 2024

Dr Winter described how at the around when the Sheffield study took place most clinicians seemed to ignore the issue of NANBH as blood products has brought such miraculous results and so the issues seemed to outweigh the benefits.

Published on: 27 September, 2024

Dr Winter stated that that the Preston paper was a key moment as the general attitude moved from mild to very concerned.

Published on: 27 September, 2024

In oral evidence Dr Mark Winter described how in the 1980s, despite the growing concern of the hepatitis virus, treatment with factor concentrates continued unabated.

Published on: 27 September, 2024

With respect to the growing prevalence of AIDS and the response of UKHCDO, Dr Winter explained how the issue with blood products was that there were constantly new viruses being discovered.

Published on: 27 September, 2024

Dr Winter described how the San Francisco cases in 1982 led to the start of haemophilia doctors understanding they were dealing with a transmissible blood disease.

Published on: 27 September, 2024

Dr Winter described how there are two major problems with concentrate therapy. Firstly, liver disease was much more significant than they thought. Secondly, they required a lot more information to understand what the disease was, how to test for it and how to respond.

Published on: 27 September, 2024

Dr Winter stressed that all haemophilia clinicians were on alert by the end of 1982 on what was occurring regarding the AIDS epidemic.

Published on: 27 September, 2024

Dr Winter explained to the Penrose inquiry that around December 1982, all doctors would have had to interpret the reports from San Francisco that three patients had received blood infected with HIV, and so conclude that HIV was a transmissible disease through blood/blood products.

Published on: 27 September, 2024

Dr Winter held that by 1982, there should have been 'alarm bells' over the potential seriousness of the HIV virus.

Published on: 27 September, 2024

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter, who worked as one of the senior registrars held that there was never enough NHS commercial concentrate.

Published on: 27 September, 2024

Dr Winter held that due to the shortage taking place at Guy's Hospital and Margate, Tooting Bec hospital had to cover the shortage.

Published on: 27 September, 2024

Dr Winter held that due to the shortage Shortfalls were covered by the use of commercial concentrate, and cryoprecipitate was in limited use only for mild haemophilia or von Willebrand disorder, or occasionally for a child or rarely treated adult.

Published on: 27 September, 2024

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that patients diagnosed with moderate haemophilia may have also received commercial concentrates

Published on: 27 September, 2024

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that patients diagnosed with mild haemophilia may have also received commercial concentrates, in instances where DDAVP was proving ineffective.

Published on: 27 September, 2024

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that while children were prioritised for being treated with NHS products and that prophylactic treatment for children, there was a possibility that children received commercial concentrates too.

Published on: 27 September, 2024

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that with regards to the treatment of children, the general practice was that children were not given concentrate unless they absolutely needed it.

Published on: 27 September, 2024

Dr Winter took the post as director at the Haemophilia Centre in Margate in December 1983.

Published on: 27 September, 2024

Dr Winter held that at the Haemophilia Centre in Margate that around the time of 1983, there was a serious lack of funding.

Published on: 27 September, 2024

Dr Winter explained that no one approached Tooting hospital to help address the issue of cryoprecipitate supplies.

Published on: 27 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2340
  • Page 2341
  • Page 2342
  • Page 2343
  • Current page 2344
  • Page 2345
  • Page 2346
  • Page 2347
  • Page 2348
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.